Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adipose-derived MSCs in Lyell Syndrome
NCT04711200Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2024
- Primary completion
- Apr 2027
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adipose derived mesenchymal stromal cells in Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Observation of at least one adverse effect at Day 10 and Rate of complete or almost complete reepithelialisation at Day 7. Started Apr 2024; status: recruiting.
02
Drugs
adipose derived mesenchymal stromal cells
03
Conditions
Stevens-Johnson syndrome (SJS)toxic epidermal necrolysis (TEN)
Beyond the preview
Go deeper on NCT04711200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04711200.